Company intelligence

AVTX

Avalo Therapeutics, Inc. · NASDAQ · Healthcare

Price$19.68-0.30% · −$0.06

Market cap1.03BEquity value

P / E-4.2Trailing ratio

Volume81.47KLatest session

Market data

AVTX price chart

TradingView

Related signals

1 min delayed

Browse public AVTX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

AVTXFeb 2, 2026-0.06% since signal

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Avalo Therapeutics has successfully completed the enrollment phase for its pivotal Phase 2 LOTUS trial for AVTX-009, its lead drug candidate. This is a significant milestone that could enhance investor confidence and positively influence the stock's performance in the upcoming months.

View signal analysis

AVTXMar 25, 2025-4.46% since signal

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Stifel initiated coverage on Avalo Therapeutics, rating it as Buy. AVTX-009 is targeting hidradenitis suppurativa with Phase 2 trials underway. Topline data for AVTX-009 is expected by 2026. Stifel anticipates strong potential in HS market with over $2 billion revenue. Avalo's current cash is sufficient to fund operations into 2027.

View signal analysis

Research